Inhibitors of the enzyme catechol-O-methyltransferase (COMT) are used as co-adjuvants in the therapy of Parkinson's disease. A recombinant form of the soluble cytosolic COMT from rat has been co-crystallized with a new potent inhibitor, BIA 8-176 [(3,4-dihydroxy-2-nitrophenyl)phenylmethanone], by the vapour-diffusion method using PEG 6K as precipitant. Crystals diffract to 1.6 Å resolution on a synchrotron-radiation source and belong to the monoclinic space group P21, with unit-cell parameters a = 52.77, b = 79.63, c = 61.54 Å, β = 91.14°. © 2005 International Union of Crystallography All rights reserved.
CITATION STYLE
Rodrigues, M. L., Bonifácio, M. J., Soares-Da-Silva, P., Carrondo, M. A., & Archer, M. (2005). Crystallization and preliminary X-ray diffraction studies of a catechol-O-methyltransferase/inhibitor complex. Acta Crystallographica Section F: Structural Biology and Crystallization Communications, 61(1), 118–120. https://doi.org/10.1107/S1744309104031197
Mendeley helps you to discover research relevant for your work.